{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:01:37Z","timestamp":1793325697342,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    After the clinical implementation of amyloid-\u03b2-targeting therapies for people with cognitive impairment due to Alzheimer\u2019s disease (AD), there is an urgent need to efficiently identify this patient population in primary care. Therefore, we created a brief and self-administered digital cognitive test battery (BioCog). Based on its sub-scores, a logistic regression model was developed in a secondary care cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009223) and then evaluated in an independent primary care cohort comprising 19 primary care centers (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009403). In primary care, BioCog had an accuracy of 85% when using a single cutoff to define cognitive impairment, which was significantly better than the assessment of primary care physicians (accuracy 73%). The accuracy increased to 90% when using a two-cutoff approach. BioCog had significantly higher accuracy than standard paper-and-pencil tests (that is, Mini-Mental State Examination, Montreal Cognitive Assessment, Mini-Cog) and another digital cognitive test. Furthermore, BioCog combined with a blood test could detect clinical, biomarker-verified AD with an accuracy of 90% (one cutoff), significantly better than standard-of-care (accuracy 70%) or when using the blood test alone (accuracy 80%). In conclusion, this proof-of-concept study shows that a brief, self-administered digital cognitive test battery can detect cognitive impairment and, when combined with a blood test, accurately identify clinical AD in primary care.\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-03965-4","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T09:04:52Z","timestamp":1757927092000},"page":"4131-4139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Primary care detection of Alzheimer\u2019s disease using a self-administered digital cognitive test and blood biomarkers"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9620-7115","authenticated-orcid":false,"given":"Pontus","family":"Tideman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-772X","authenticated-orcid":false,"given":"Linda","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Calling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0112","authenticated-orcid":false,"given":"Ruben","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-8731","authenticated-orcid":false,"given":"Patrik","family":"Midl\u00f6v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4793-564X","authenticated-orcid":false,"given":"Philip B.","family":"Verghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel B.","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-7724","authenticated-orcid":false,"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"3965_CR1","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack, C. R. Jr et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"3965_CR2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"3965_CR3","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 18, 2669\u20132686 (2022).","journal-title":"Alzheimers Dement."},{"key":"3965_CR4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13195-023-01272-z","volume":"15","author":"S Mattke","year":"2023","unstructured":"Mattke, S. et al. Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis. Alzheimers Res. Ther. 15, 128 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"3965_CR5","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1002\/alz.14150","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke, M. M. et al. Considerations for widespread implementation of blood-based biomarkers of Alzheimer\u2019s disease. Alzheimers Dement. 20, 8209\u20138215 (2024).","journal-title":"Alzheimers Dement."},{"key":"3965_CR6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist, S. et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA 332, 1245\u20131257 (2024).","journal-title":"JAMA"},{"key":"3965_CR7","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321, 1161\u20131169 (2019).","journal-title":"JAMA"},{"key":"3965_CR8","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954\u2013963 (2021).","journal-title":"Nat. Med."},{"key":"3965_CR9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat. Aging 3, 506\u2013519 (2023).","journal-title":"Nat. Aging"},{"key":"3965_CR10","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy, N. R. et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. 30, 1085\u20131095 (2024).","journal-title":"Nat. Med."},{"key":"3965_CR11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler, S. E. et al. Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat. Rev. Neurol. 20, 426\u2013439 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"3965_CR12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen, W. J. et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 79, 228\u2013243 (2022).","journal-title":"JAMA Neurol."},{"key":"3965_CR13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois, B. et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 20, 484\u2013496 (2021).","journal-title":"Lancet Neurol."},{"key":"3965_CR14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"3965_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3965_CR16","doi-asserted-by":"crossref","unstructured":"Hansson, O. & Jack, C. R. Jr. A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer\u2019s disease. Nat. Aging 4, 1029\u20131031 (2024).","DOI":"10.1038\/s43587-024-00675-3"},{"key":"3965_CR17","unstructured":"World Health Organization. Preferred Product Characteristics of Blood-Based Biomarker Diagnostics for Alzheimer Disease (2024)."},{"key":"3965_CR18","doi-asserted-by":"crossref","first-page":"e70535","DOI":"10.1002\/alz.70535","volume":"21","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist, S. et al. Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings. Alzheimers Dement. 21, e70535 (2025).","journal-title":"Alzheimers Dement."},{"key":"3965_CR19","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1002\/alz.13051","volume":"19","author":"S Mattke","year":"2023","unstructured":"Mattke, S. et al. Expanding the use of brief cognitive assessments to detect suspected early-stage cognitive impairment in primary care. Alzheimers Dement. 19, 4252\u20134259 (2023).","journal-title":"Alzheimers Dement."},{"key":"3965_CR20","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"3965_CR21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-020-00603-8","volume":"12","author":"AE Thomann","year":"2020","unstructured":"Thomann, A. E., Berres, M., Goettel, N., Steiner, L. A. & Monsch, A. U. Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the montreal cognitive assessment. Alzheimers Res. Ther. 12, 39 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"3965_CR22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren, N. et al. Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies. JAMA Neurol. 81, 69\u201378 (2024).","journal-title":"JAMA Neurol."},{"key":"3965_CR23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid beta positivity with further confirmatory testing only in uncertain cases. Nat. Aging 3, 1079\u20131090 (2023).","journal-title":"Nat. Aging"},{"key":"3965_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5498\/wjp.v10.i1.1","volume":"10","author":"D Cahn-Hidalgo","year":"2020","unstructured":"Cahn-Hidalgo, D., Estes, P. W. & Benabou, R. Validity, reliability, and psychometric properties of a computerized, cognitive assessment test (Cognivue\u00ae). World J. Psychiatry 10, 1 (2020).","journal-title":"World J. Psychiatry"},{"key":"3965_CR25","first-page":"S54","volume":"80","author":"S Weintraub","year":"2013","unstructured":"Weintraub, S. et al. Cognition assessment using the NIH Toolbox. Neurology 80, S54\u2013S64 (2013).","journal-title":"Neurology"},{"key":"3965_CR26","volume":"12","author":"HFM Rhodius-Meester","year":"2020","unstructured":"Rhodius-Meester, H. F. M. et al. cCOG: a web-based cognitive test tool for detecting neurodegenerative disorders. Alzheimers Dement. (Amst.) 12, e12083 (2020).","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"3965_CR27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/arclin\/acp010","volume":"24","author":"P Maruff","year":"2009","unstructured":"Maruff, P. et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch. Clin. Neuropsychol. 24, 165\u2013178 (2009).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"3965_CR28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jgs.15208","volume":"66","author":"KL Possin","year":"2018","unstructured":"Possin, K. L. et al. The brain health assessment for detecting and diagnosing neurocognitive disorders. J. Am. Geriatr. Soc. 66, 150\u2013156 (2018).","journal-title":"J. Am. Geriatr. Soc."},{"key":"3965_CR29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings, J. et al. Lecanemab: appropriate use recommendations. J. Prev. Alzheimers Dis. 10, 362\u2013377 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"3965_CR30","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","volume":"111","author":"H Hampel","year":"2023","unstructured":"Hampel, H. et al. Blood-based biomarkers for Alzheimer\u2019s disease: current state and future use in a transformed global healthcare landscape. Neuron 111, 2781\u20132799 (2023).","journal-title":"Neuron"},{"key":"3965_CR31","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","volume":"4","author":"J Therriault","year":"2024","unstructured":"Therriault, J. et al. Diagnosis of Alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability. Nat. Aging 4, 1529\u20131537 (2024).","journal-title":"Nat. Aging"},{"key":"3965_CR32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes, C. P., Berg, L., Danziger, W., Coben, L. A. & Martin, R. L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 140, 566\u2013572 (1982).","journal-title":"Br. J. Psychiatry"},{"key":"3965_CR33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/S1041610297004870","volume":"9","author":"JC Morris","year":"1997","unstructured":"Morris, J. C. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int. Psychogeriatr. 9, 173\u2013176 (1997).","journal-title":"Int. Psychogeriatr."},{"key":"3965_CR34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/arclin\/acw007","volume":"31","author":"LA Rabin","year":"2016","unstructured":"Rabin, L. A., Paolillo, E. & Barr, W. B. Stability in test-usage practices of clinical neuropsychologists in the United States and Canada over a 10-year period: a follow-up survey of INS and NAN members. Arch. Clin. Neuropsychol. 31, 206\u2013230 (2016).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"3965_CR35","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/alz.12164","volume":"16","author":"AM Wessels","year":"2020","unstructured":"Wessels, A. M. et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer\u2019s disease. Alzheimers Dement. 16, 1483\u20131492 (2020).","journal-title":"Alzheimers Dement."},{"key":"3965_CR36","doi-asserted-by":"crossref","first-page":"8625","DOI":"10.1002\/alz.14305","volume":"20","author":"E Borland","year":"2024","unstructured":"Borland, E. et al. Individualized, cross\u2010validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms. Alzheimers Dement. 20, 8625\u20138638 (2024).","journal-title":"Alzheimers Dement."},{"key":"3965_CR37","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/alz.13686","volume":"20","author":"E Tsoy","year":"2024","unstructured":"Tsoy, E. et al. Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer\u2019s disease and related dementias. Alzheimers Dement. 20, 2089\u20132101 (2024).","journal-title":"Alzheimers Dement."},{"key":"3965_CR38","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100038","volume":"12","author":"T Ozawa","year":"2025","unstructured":"Ozawa, T. et al. Effects of the Davos Alzheimer\u2019s Collaborative early detection of cognitive impairment program on clinician attitudes, engagement, and confidence. J. Prev. Alzheimers Dis. 12, 100038 (2025).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"3965_CR39","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-159-9-201311050-00730","volume":"159","author":"JS Lin","year":"2013","unstructured":"Lin, J. S., O\u2019Connor, E., Rossom, R. C., Perdue, L. A. & Eckstrom, E. Screening for cognitive impairment in older adults: a systematic review for the US preventive services task force. Ann. Intern. Med. 159, 601\u2013612 (2013).","journal-title":"Ann. Intern. Med."},{"key":"3965_CR40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u2018Mini-Mental State\u2019: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"3965_CR41","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695\u2013699 (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"3965_CR42","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6","volume":"15","author":"S Borson","year":"2000","unstructured":"Borson, S., Scanlan, J., Brush, M., Vitaliano, P. & Dokmak, A. The Mini-Cog: a cognitive \u2018vital signs\u2019 measure for dementia screening in multi-lingual elderly. Int J. Geriatr. Psychiatry 15, 1021\u20131027 (2000).","journal-title":"Int J. Geriatr. Psychiatry"},{"key":"3965_CR43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/brain\/111.3.695","volume":"111","author":"BJ Sahakian","year":"1988","unstructured":"Sahakian, B. J. et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson\u2019s disease. Brain 111, 695\u2013718 (1988).","journal-title":"Brain"},{"key":"3965_CR44","first-page":"963","volume":"65","author":"SE O'Bryant","year":"2008","unstructured":"O'Bryant, S. E. et al. Detecting dementia with the Mini-Mental State Examination in highly educated individuals. Arch. Neurol. 65, 963\u2013967 (2008).","journal-title":"Arch. Neurol."},{"key":"3965_CR45","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1532-5415.2011.03841.x","volume":"60","author":"JR McCarten","year":"2012","unstructured":"McCarten, J. R. et al. Finding dementia in primary care: the results of a clinical demonstration project. J. Am. Geriatr. Soc. 60, 210\u2013217 (2012).","journal-title":"J. Am. Geriatr. Soc."},{"key":"3965_CR46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000342116","volume":"34","author":"J Junkkila","year":"2012","unstructured":"Junkkila, J., Oja, S., Laine, M. & Karrasch, M. Applicability of the CANTAB-PAL computerized memory test in identifying amnestic mild cognitive impairment and Alzheimer\u2019s disease. Dement. Geriatr. Cogn. Disord. 34, 83\u201389 (2012).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"3965_CR47","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1002\/alz.13764","volume":"20","author":"MR Meyer","year":"2024","unstructured":"Meyer, M. R. et al. Clinical validation of the PrecivityAD2\u2122 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and Ab42\/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 20, 3179\u20133192 (2024).","journal-title":"Alzheimers Dement."},{"key":"3965_CR48","volume-title":"Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)","author":"C Randolph","year":"1998","unstructured":"Randolph, C. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (Psychological Corporation, 1998)."},{"key":"3965_CR49","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.acn.2008.06.004","volume":"23","author":"K Duff","year":"2008","unstructured":"Duff, K. et al. Utility of the RBANS in detecting cognitive impairment associated with Alzheimer\u2019s disease: sensitivity, specificity, and positive and negative predictive powers. Arch. Clin. Neuropsychol. 23, 603\u2013612 (2008).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"3965_CR50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/arclin\/act057","volume":"28","author":"S Karantzoulis","year":"2013","unstructured":"Karantzoulis, S., Novitski, J., Gold, M. & Randolph, C. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): utility in detection and characterization of mild cognitive impairment due to Alzheimer\u2019s disease. Arch. Clin. Neuropsychol. 28, 837\u2013844 (2013).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"3965_CR51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen, R. C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303\u2013308 (1999).","journal-title":"Arch. Neurol."},{"key":"3965_CR52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/JGP.0b013e31819431d5","volume":"17","author":"AJ Jak","year":"2009","unstructured":"Jak, A. J. et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am. J. Geriatr. Psychiatry 17, 368\u2013375 (2009).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"3965_CR53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.12688\/f1000research.2-71.v2","volume":"2","author":"E Olofsen","year":"2014","unstructured":"Olofsen, E. & Dahan, A. Using Akaike\u2019s information theoretic criterion in mixed-effects modeling of pharmacokinetic data: a simulation study. F1000Research 2, 71 (2014).","journal-title":"F1000Research"},{"key":"3965_CR54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/0049124104268644","volume":"33","author":"KP Burnham","year":"2004","unstructured":"Burnham, K. P. & Anderson, D. R. Multimodel inference: understanding AIC and BIC in model selection. Sociol. Methods Res. 33, 261\u2013304 (2004).","journal-title":"Sociol. Methods Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03965-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03965-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03965-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:22Z","timestamp":1765814422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03965-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3965"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03965-4","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.P. has acquired research support (for the institution) from Avid and ki elements through ADDF. In the past 2\u2009years, he has received consultancy and\/or speaker fees from Bioartic, Biogen, Esai, Eli Lilly, Novo Nordisk and Roche. R.S. has received consultancy and\/or speaker fees from Lilly, Novo Nordisk, Roche and Triolab. N.M.-C. received consultancy and\/or speaker fees from Biogen, Merck and Owkin. O.H. is an employee of Eli Lilly and Lund University. P.B.V. and J.B.B. are salaried employees for C2N Diagnostics and receiving compensation from the company in the form of a salary or equity. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}